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[57] ABSTRACT 
The present invention provides, inter alia, formulations 
useful to ameliorate symptoms associated With mucosal 
abrasions, speci?cally those due to dental orthodontic brack 
ets; oral surgery; periodontal surgery or other procedures. 
For instance, there is a formulation comprising: 65 to 75% 
microcrystalline Wax; 5 to 15% non-ionic polymer; 15 to 
25% topical anesthetic; and 1 to 5% surfactant, Wherein the 
ratio of non-ionic polymer to microcrystalline Wax is no 
greater than 0.2. Preferably, for solid topical anesthetics, the 
particle siZe is less than the apertures of a 100-mesh screen. 
HoWever, the topical anesthetic may also be a liquid. For 
mulations Wherein the mixture is a homogeneous matrix is 
preferred. 
21 Claims, 4 Drawing Sheets 
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FORMULATIONS FOR SUSTAINED 
RELEASE OF TOPICAL ANESTHETICS AND 
METHODS OF MAKING AND USING SAME 
This Application claims priority to Provisional Patent 
Application No. 60/063,904, ?led Oct. 31, 1997. 
BACKGROUND OF THE INVENTION 
Orthodontic patients Who require corrective braces almost 
alWays develop mouth abrasions due to friction betWeen the 
orthodontic brackets and the oral mucosa. Previous treat 
ments have included the use of Wax to cover the brackets, 
and the use of topical anesthetics to treat the Wounds. 
Currently, dental Wax is used by most, if not all, orth 
odontic patients to treat the problem of mouth abrasions. 
Typically, soft Wax is applied to the brackets to reduce the 
friction. This is done on a prophylactic or as-needed basis 
and is often used in conjunction With a topical anesthetic that 
is applied directly to the irritated mucosa. 
Topical anesthetic formulations to date have proved tran 
sitory in action; that is, the effect lasts for a matter of 
minutes. The ?eeting action is due to the Water soluble 
nature of the topical anesthetics, and the Water-rich envi 
ronment into Which they are introduced. 
One patent, US. Pat. No. 4,740,365 describes a prepara 
tion Which provides sustained release of pharmaceuticals 
(including benZocaine) via a layered copolymer. Use of this 
?lm on dental brackets is inappropriate, for structural 
reasons, nor Would it solve the unique problems of dental 
bracket abrasions. 
Moreover, Waxes and Wax/polymer/surfactant formula 
tions have been used in dentistry for the purpose of making 
impressions of a patient’s teeth. Waxes may be then used as 
a mold for casting arti?cial teeth or for diagnostic purposes. 
Previous Wax formulations of this sort did not incorporate an 
anesthetic, since the use did not Warrant such incorporation. 
The Waxes used in dentistry normally consist of tWo or 
more components Which may be natural or synthetic Waxes, 
resins, oils, fats and pigments. Blending is carried out to 
produce a material With the required properties for a speci?c 
application. J. F. McCabe. Applied dental materials (7th ed.). 
BlackWell Scienti?c Publications, Oxford. Waxes are ther 
moplastic materials Which are normally solids at room 
temperature but melt, Without decomposition, to form 
mobile liquids. They are, essentially, soft substances With 
poor mechanical properties and their primary uses in den 
tistry are to form patterns of appliances prior to casting. An 
important group of Waxes used in dentistry are the impres 
sion Waxes. Waxes are generally characteriZed by their 
thermal properties such as melting point and solid-solid 
transition temperature Which is closely related to the soft 
ening temperature observed in practice. Important mechani 
cal properties are brittleness and the degree of How Which a 
material Will undergo in its Working temperature range. See, 
for example, Kotsiomiti & McCabe, 23 J. Oral Rehabil. 114 
(1996). 
In McCrorie, 29 J. Oral Rehab. 29 (1974), there is a 
revieW of the sparse information knoWn prior to this publi 
cation regarding modelling Waxes, and some objective data 
for several knoWn modelling Waxes. The paper compares the 
modelling Waxes to ordinary Waxes, such as paraffins and 
beesWaxes. The author gives his suggestions (on page 44) to 
those Who are trying to identify useful modelling Waxes. 
In Lolor et al., 84(6), J. Pharm. Sci. 673 (1995), there is 
disclosed a study of factors desirable in a transdermal 
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preparation. Lolor deals primarily With Water/oil/surfactant 
preparations, and does not discuss Wax embodiments. 
Citation of the above documents is not intended as an 
admission that any of the foregoing is pertinent prior art. All 
statements as to the date or representation as to the contents 
of these documents is based on subjective characteriZation 
of information available to the applicant, and does not 
constitute any admission as to the accuracy of the dates or 
contents of these documents. 
SUMMARY OF THE INVENTION 
It is therefore an object of the present invention to provide 
formulations useful to treat mucosal abrasions. 
It is a further object to provide a method for making 
formulations to treat mucosal abrasions. 
It is yet another object to provide methods to treat 
mucosal abrasions. 
It is yet another object to provide methods to reduce pain 
due to mucosal abrasions. 
De?nitions: For the purposes of the present application, 
the folloWing terms shall have the meanings as described 
beloW. All other terms shall have the meanings commonly 
recogniZed in the art at the time of ?ling. 
“Non-ionic polymer(s)” shall mean non-ionic polymer(s) 
that are hydrophilic or lipophilic. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a bar graph shoWing the comparison of release 
rate of benZocaine for 30 minutes in several matrices. 
FIG. 2 is a bar graph shoWing the released amount of 
benZocaine after 8 hours for several polymer/Wax matrices. 
FIG. 3 is a bar graph shoWing the comparison of loss of 
Weight for several polymer/Wax matrices. 
FIG. 4 is a comparison of initial melting point, melting 
point of matrices and melting point of benZocaine. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention therefore provides, inter alia, for 
mulations useful to ameliorate symptoms associated With 
mucosal abrasions, speci?cally those due to dental orth 
odontic brackets; oral surgery; periodontal surgery or other 
procedures. For instance, there is a formulation comprising: 
65 to 75% microcrystalline Wax; 5 to 15% non-ionic poly 
mer; 15 to 25% topical anesthetic; and 1 to 5% surfactant, 
Wherein the ratio of non-ionic polymer to microcrystalline 
Wax is no greater than 0.2. Preferably, for solid topical 
anesthetics, the particle siZe is less than the apertures of a 
100-mesh screen. HoWever, the topical anesthetic may also 
be a liquid. Formulations Wherein the mixture is a homo 
geneous matrix is preferred. 
Speci?cally provided is a formulation as above, Wherein 
the microcrystalline Wax, non-ionic polymer and topical 
anesthetic are prepared according to the methods described 
herein. 
Preferred formulations are those Wherein the topical anes 
thetic is selected from the group consisting of: benZocaine; 
lidocaine; novocaine; procaine; butalaine; and dyclonine. 
Also preferred are those formulations Wherein the non-ionic 
polymer is selected from the group consisting of: sodium 
carboxymethyl cellulose; Carbopol ETD 2001 resin; traga 
canth; poly (ethylene oxide); methylcellulose; hydroxy 
propylmethylcellulose; karya gum; cellulose; soluble starch; 
gelatin; poly (vinyl pyrrolidone); poly (ethylene glycol) 
6,074,674 
3 
8000; poly (ethylene glycol) 4000; and poly (vinyl alcohol). 
Formulations Wherein the surfactant is selected from the 
group consisting of: sorbitan monolaurate, polysorbate 80 
Spans and TWeens are also preferred. 
A formulation Wherein the topical anesthetic is ben 
Zocaine is herein provided. A formulation Wherein the topi 
cal anesthetic is benZocaine, and the non-ionic polymer is 
tragacanth is more preferred. A formulation Wherein the 
topical anesthetic is benZocaine, the non-ionic polymer is 
tragacanth, and the surfactant is Span80 is most preferred. 
Speci?cally, a formulation Wherein, of the total, the traga 
canth is 7.1%, the microcrystalline Wax is 70.9%, the 
Span80 is 2.0% and the benZocaine is 20.0% is provided. 
HoWever, formulations Which comprise liquid anesthetics 
are also provided. 
In making the above formulations, it is desirable to make 
a uniform matrix. The Wax/polymer/surfactant mixture can 
be made according to means knoWn in the art of making 
Waxes. For example, the references cited in the background 
section of this application Will be useful. For instance, the 
polymer to Wax ratio may be up to 0.2. The methods 
described herein result in the proper physical parameters, 
and can also be used to manufacture the above formulations. 
The present invention also provides methods to prepare 
formulations useful to treat symptoms associated With dental 
abrasions. Speci?cally, there are provided methods compris 
ing the steps of: adding a topical anesthetic With particle siZe 
less than the apertures in a 100 mesh screen to a homoge 
neous mixture of melted microcrystalline Wax, non-ionic 
polymer and surfactant, in a plurality of portions and With 
mixing, so as to obtain a homogenous mixture of said 
anesthetic, Wax, polymer and surfactant; and cooling said 
homogenous mixture of said anesthetic, Wax, polymer and 
surfactant at a constant rate, With continuous agitation, so as 
to congeal the mixture into a homogeneous matrix. 
By “homogeneous mixture” and “homogeneous matrix” it 
is meant that every sample of the mixture or matrix is of 
similar composition, that is, the ratio of components is the 
same, for like sample siZes. 
Alternatively, the formulations of the present invention 
can be manufactured as folloWs: Wax can be added to a 
manufacturing kettle With heating/cooling capabilities. The 
kettle should also be equipped With a bottom-to top recir 
culating pump and a mixer With a shaft and blade. The Wax 
should be heated to approximately 65 to 70° C. The polymer 
and surfactant should be individually folloWed by the anes 
thetic. Then, the mixing process should be continued until all 
material is in a homogeneous state. The mixture should be 
gradually cooled (approximately 1° C. ° C./minute) and the 
cooled materials ?ltered using the re-circulation pump, into 
a clean receiving tank. The materials are optimally retained 
at a moldable consistency for further processing, testing or 
dispensing. Then, the materials are transfered for dispens 
ing. 
Topical anesthetics used in the present methods can be 
any molecules Which provide pain relief for the oral mucosa. 
In a speci?c embodiment, the topical anesthetic can be, for 
example, benZocaine; lidocaine; novocaine; procaine; buta 
laine; and dyclonine. 
Non-ionic polymers used in the present methods can be 
any molecules Which are Without electrical charge, that is, 
they are neutral. In a speci?c embodiment, the non-ionic 
polymer can be, for example: sodium carboxymethyl cellu 
lose; Carbopol ETD 2001 resin; tragacanth; poly (ethylene 
oxide); methylcellulose; hydroxypropylmethylcellulose; 
karya gum; cellulose; soluble starch; gelatin; poly (vinyl 
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pyrrolidone); poly (ethylene glycol) 8000; poly (ethylene 
glycol) 4000; and poly (vinyl alcohol). 
In a preferred embodiment of the present invention, there 
is provided a method Wherein the microcrystalline Wax is 
?rst melted 65—70° C.; the polymer and surfactant are 
subsequently added With stirring; the sieve-shaker-screened 
benZocaine is subsequently added With stirring so as to 
produce a mixture; the mixture then stired for 5 to 10 
minutes at 65 to 70° C.; the mixture then cooled With 
constant manual mixing so as to form a solid With a 
homogeneous matrix. The solid homogeneous matrix may 
then optionally be formed into uniform pieces of a siZe 
appropriate to place on individual dental brackets. 
In another preferred embodiment, there is provided a 
method Wherein the topical anesthetic is benZocaine. A 
method Wherein the anesthetic is benZocaine and the non 
ionic polymer is tragacanth is speci?cally preferred. More 
preferred is a method Wherein the anesthetic is benZocaine, 
the non-ionic polymer is tragacanth and the surfactant is 
Span80. Most preferred is method Wherein, of the total the 
tragacanth is 7.1%, the microcrystalline Wax is 70.9%, the 
Span80 is 2.0% and the benZocaine is 20.0%. 
Also provided are methods of reducing pain due mucosal 
abrasions in a patient in need of such pain reduction, 
comprising administering a formulation as described above. 
Speci?cally, methods of reducing pain due to mucosal 
abrasions in a patient in need of such pain reduction, 
comprising administering a formulation Wherein the topical 
anesthetic is benZocaine, the non-ionic polymer is 
tragacanth, and the surfactant is Span 80 is most preferred. 
EXAMPLES 
Example 1 
OptimiZaton of Sustained Release of BenZocaine 
from Tragacanth/Wax/Span80 Formulation 
TABLE I 
The materials used 
Mean 
muco- % Melt 
Polymers & Abbre- adhesive Molecular ing Com 
Materials viationa force Weight point pany 
Sodium carboxy- SCMC 192.4 1 12.0 90,000 Aldrich 
methyl cellulose 
Carbopol ETD CP 185.0 1 10.3 Good 
2001 Resin rich 
Tragacanth TC 154.4 1 7.5 Aldrich 
Poly (ethylene PEO 128.6 1 4.0 100,000 Aldrich 
oxide) 
Methylcellulose MC 128.0 1 2.4 40,000 Aldrich 
Hydroxypropyl- HPMC 125.2 1 16.7 Aldrich 
methylcellulose 
Karya gum KG 125.2 1 4.8 Aldrich 
Cellulose C — Aldrich 
Soluble starch STRC 117.2 1 3.1 Aldrich 
Gelatin GT 115.8 1 5.6 Aldrich 
Poly (vinyl PVP 97.6 r 3.9 55,000 Aldrich 
pyrrolidone) 
Poly (ethylene PEG8 96.0 r 7.6 8,000 Aldrich 
glycol) 8000 
Poly (ethylene PEG4 — 4,000 Aldrich 
glycol) 4000 
Poly (vinyl PVA 94.8 r 4.4 89,000 ~ Aldrich 
alcohol) 98,000 
Poly PHEMA 88.4 r 2.3 300,000 Aldrich 
(hydroxyethyl 
methacrylate) 
6,074,674 
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TABLE I-continued 
The materials used 
Mean 
muco- % Melt 
Polymers & Abbre- adhesive Molecular ing Com 
Materials viationa force Weight point pany 
Hydroxypropyl- HPC 87.1 r 13.3 370,000 Aldrich 
cellulose 
Microcrystalline MCWX — Dents 
Wax ply 
Benzocaine BZ — 165.2 Aldrich 
Span 80 SP80 — SIGMA 
aAbbreviation Was used as a matrix name 
Matrix Preparation 
The drug and surfactant Were physically dispersed into a 
molten Wax matrix. The percentage of polymer, microcrys 
talline Wax (MCWX), Span 80 (SP80), benZocaine (BZ) 
mixtures Was 7.1, 70.9, 2.0, 20.0 respectively. The ratio of 
polymer to MCWX Was ?xed as 1: 10. The hydrophilic 
polymer-Wax-surfactant-drug mixtures Were prepared by 
melting microcrystalline Wax to approximately 65—70° C. 
Benzocaine, after passing through a 100-mesh screen by 
sieve shaker (Vibratory 3-IN, Sieve Shaker, SS-5, Gilson 
Co.), Was added in small portions While the mass Was mixed 
for 5 to 10 minutes. SloWly, the entire mass Was then 
solidi?ed in a vessel With constant mixing. The mixture Was 
alloWed to cool doWn to room temperature. This method Was 
selected because it produced a more uniform matrix than 
other methods. After one day after, the mass Was compressed 
into 100 mg cores using 9.5 mm punches and die using a 
pressure of 1,000 lbs. The upper punch Was ?at and the 
loWer punch Was concave. These compressed Waxes Were 
used in the Loss of Weight experiments. 
Dissolution Procedure 
The USP rotating-basket method Was employed for inves 
tigating drug release from the matrices. A matrix Was 
attached on the ?at shaft With the basket, Which Was 
immersed in 500 ml of Water Which Was degassed, simulated 
saliva. The basket Was rotated at 60 rpm, and the Water bath 
of the dissolution apparatus (Vander Kamp® 600 Six 
spindle Dissolution tester, Van-Kel Inc., USA) Was main 
tained at 37° C. for 8 hrs. Samples Were draWn at 0, 5, 10, 
15, 20, 30, 60, 90, 120, 180, 240, 300, 360, 420, 480, 
minutes. At each interval, a 3 ml sample Was Withdrawn 
from the vessel for assay, and immediately replaced With an 
equivalent volume of dissolution medium. Three runs Were 
made on each batch. The samples obtained through 30 
minutes Were used to calculate the Zero-order release rate 
(Rr). 
Benzocaine Assay 
The dissolution medium Was degassed distilled Water. 
Samples obtained from the dissolution apparatus Were 
diluted With distilled Water and assayed for benZocaine 
content by measuring absorbance at 284.6 nm With UV/V IS 
spectrophotometer (U-2000 Spectrophotometer, Hitachi, 
Japan). The concentration in the sample Was calculated from 
a standard Beer’s laW plot. 
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Example 2 
Release of Benzocaine from Formulation of 
Varying Polymer Constituents 
This study shoWs the physical properties of the Wax/ 
polymer/span80 matrix. The thermal properties Were mea 
sured. The results of thermal analysis, loss of Weight, release 
rate for 30 minutes, cumulative released percentage amount 
for 8 hours and the degree of erosion after 8 hours during the 
dissolution test are given. 
Thermal Analysis: A differential scanning calorimeter 
(DSC 7, differential scanning calorimeter, Perkin-Elmer, 
USA) Was used to determine the energy changes. The 
samples Were placed in aluminum pans and scanned from 10 
to 100° C. at 5° C./min. The How rate of helium gas to purge 
Was 30 cc/min and thermograms Were recorded. Three runs 
for each material Were performed. 
Loss of Weight Test (L/W): Before the dissolution tests 
Were conducted, a study Was conducted to determine the 
stickiness of the matrix, i.e., hoW easily it might be removed 
from surface like a tooth or orthodontic bracket. A 100 mg 
matrix Was compressed as described above except that a 
piece of Waxed Weighing paper Was placed over the edge of 
each punch. The matrix Was placed into an empty jacketed 
beaker for 5 min at 37° C., and then immediately, the ?at 
side of the matrix Was attached to a glass plate With tWo 
sided adhesive tape. After 2 min, the Wax paper (cover) on 
the concave side of the matrix Was peeled off by forceps over 
a 20 second period. The detached Wax paper Was Weighed 
With the balance (Mettler, Type H6, No. 28088, Metler 
Instrument Co., Switzerland) and the amount of Weight lost 
by the matrix Was recorded. This Was repeated for six 
samples of each formulation. 
Erosion After 8 hours (E8) During Release Test: The 
erosion of the matrices after 8 hours of the release test Was 
recorded by visual observation. 
Determination of Matrix Homogeneity: The homogeneity 
of the matrices Was determined by comparing DSC thermo 
grams and by measuring the concentration of benZocaine in 
various samples. For UV assay, a 100 mg sample Was 
dissolved in 5 mL chloroform. After ?ltering With polytet 
ra?uoroethylene (PTFE) ?ltrater (0.45 um Polytetra?uoro 
ethylene sterile syringe ?lters 13 mm, Altech Associates, 
Inc.), the sample Was assayed in a UV/V IS spectrophotom 
eter as previously described. 
Table II lists the results of the various measurements 
described above including the release rate of benZocaine 
over the ?rst 30 minutes (Rr0.5), the cumulative amount 
released over 8 hrs (Ar8), the plateau time (Hplmau), the 
erosion condition after 8 hrs (E8), and the loss of Weight 
(L/W) test indicative of matrix stickiness. This table also 
includes data obtained from thermal analysis of the formu 
lations including the points at Which the matrix began to 
melt and Was completely melted (Timp/mp), and the melting 
point of benZocaine in the matrix 
6,074,674 
TABLE II 
Experimental levels of the experimental variables and values of the seven measured 
responses for the prepared formulations of polymer/Wax matrices 
Rr 0.5 
(%/min) Ar8 (%) Hplateau L/W (%) Timp/mp Tbz (0 C.) 
Formula Mean Mean 1 SD (hour) E8a Mean 1 SD (0 C.) Mean Mean 
SCMC 0.06 13.5 1 1.3 >8 + 1.12 1 0.59 26/49 81 
CP 0.03 9.8 1 1.3 >8 + 0.17 1 0.12 27/50 83 
TC 0.13 22.7 1 1.8 >8 +++ 0.35 1 0.08 27/50 81 
PEO 0.05 10.4 1 1.5 >8 + 0.53 1 0.34 27/34/50 83 
MC 0.05 9.6 1 0.4 >8 + 0.25 1 0.08 28/49 82 
HPMC 0.04 7.3 1 0.2 >8 + 0.70 1 0.23 27/51 83 
KG 0.05 7.0 1 0.5 >8 + 0.42 1 0.10 28/49 79 
C 0.05 5.7 1 0.3 >8 + 0.25 1 0.15 28/50 82 
STRC 0.05 7.2 1 0.8 >8 + 1.33 1 0.59 27/51 83 
GT 0.05 7.1 1 0.3 >8 + 0.40 1 0.09 27/49 81 
PVP 0.03 6.2 1 0.1 >8 ++ 0.15 1 0.05 27/50 79 
PEG8 0.05 7.6 1 0.9 >8 + 0.25 1 0.18 27/50 85 
PEG4 0.07 9.3 1 0.5 >8 + 4.90 1 2.46 27/49 81 
PVA 0.04 6.6 1 0.2 >8 + 0.27 1 0.21 27/49 82 
PHEMA 0.04 6.2 1 0.3 >8 + 0.50 1 0.14 27/49 82 
HPC 0.07 8.4 1 0.2 >8 + 0.48 1 0.10 27/49 84 
MCWX 0.04 6.5 1 0.3 >8 — 0.80 1 0.55 26/50 85 
CNTRL 1.24 85.5 1 2.5‘) 4 ++++ _ _ _ 
Pure Wax —° — — — — 24/50 — 
Bz _ _ _ _ _ _ 88 
3+; Not eroded, kept it’s shape. 
++; sligltly eroded. 
+++; eroded. 
++++; completely eroded. 
bAfter 4 hours 
CNot measured 
The cumulative amounts of benZocaine released during employed as the hydrophilic polymer in the matrix (FIGS. 1 
the 8 hour dissolution test are presented in Table III. and 2). None of the formulations yielded asymptotic values 
TABLE III 
Percent cumulative release (%) of benzocaine from matrices containing 
various hydrophilic polymers and span 80 
Time 
min 
Formula 10 20 30 40 60 90 120 180 240 300 360 420 480 
SCMC 1.3 1.9 2.4 2.9 3.7 4.6 5.7 7.4 8.9 10.0 11.4 12.7 13.5 
CP 1.0 1.3 1.8 1.9 2.4 2.9 3.4 4.3 5.1 6.1 7.0 8.3 9.8 
TC 1.7 3.0 4.4 5.1 6.8 8.3 9.6 12.1 14.2 16.1 18.6 21.0 22.7 
PEO 1.3 1.8 2.2 2.5 3.1 3.9 4.7 5.7 6.7 7.4 8.4 9.0 9.6 
MC 1.3 1.7 2.1 2.6 3.1 3.9 4.8 5.9 7.1 8.1 9.0 9.6 10.4 
HPMC 1.0 1.4 1.7 2.0 2.6 3.1 3.7 4.6 5.3 5.9 6.4 6.9 7.3 
KG 1.1 1.6 2.1 2.4 2.9 3.4 3.9 4.6 5.2 5.8 6.1 6.5 7.0 
C 1.2 1.7 2.1 2.4 2.7 3.1 3.6 4.1 4.5 4.9 5.2 5.5 5.7 
STRC 1.4 2.0 2.4 2.8 3.4 4.1 4.6 5.3 5.8 6.3 6.5 6.9 7.2 
GT 1.4 2.0 2.3 2.7 3.2 3.8 4.4 5.1 5.6 6.1 6.5 6.7 7.1 
PVP 1.0 1.4 1.6 1.8 2.2 2.7 3.2 3.8 4.5 4.9 5.4 5.8 6.2 
PEG8 1.2 1.8 2.2 2.5 3.0 3.7 4.2 5.0 5.7 6.3 6.7 7.2 7.6 
PEG4 2.4 2.8 3.2 3.6 4.3 4.9 5.4 6.3 7.2 7.8 8.3 8.9 9.3 
PEG 1.5 1.3 1.9 2.2 2.8 3.6 4.4 4.7 5.8 6.5 7.0 7.7 8.4 8.9 
PVA 1.2 1.6 1.9 2.2 2.6 3.1 3.6 4.3 4.8 5.3 5.7 6.2 6.6 
PHEMA 1.3 1.7 2.0 2.3 2.7 3.2 3.7 4.3 4.8 5.2 5.5 5.9 6.2 
HPC 1.2 1.7 2.2 2.6 3.4 3.7 4.5 5.6 6.2 6.6 7.2 7.8 8.4 
Blank2 1.3 1.7 2.0 2.4 2.8 3.3 3.7 4.3 4.7 5.3 5.7 6.0 6.5 
Control3 32.1 42.7 50.0 57.1 64.1 70.9 75.7 82.4 85.5 — — — — 
1Abbreviation means that it’s polymer is mixed With microcrystalline Wax, 2% span 80 and 20% ben 
Zocaine. 
2Without polymer. 
CConventional dosage form Which is PEG gel contained 20% benZocaine. 
Conclusions 65 (Hplateau) in the release tests by eight hours. For comparison, 
The greatest release rate over the ?rst 30 minutes and over the Control formulation (CNTRL), Which consisted of 20% 
an 8 hour period Was observed When tragacanth (TC) Was benZocaine in a Water-soluble PEG matrix, showed a Hpla 
6,074,674 
teau value of 4 hours. Most of the matrices showed no signs 
of erosion after 8 hours in the dissolution apparatus; the 
exception Was the matrix containing TC. This Was likely 
related to its high benZocaine release rate. 
The Loss of Weight test Was conducted to determine if the 
Wax matrix Would adhere to a surface (e.g. orthodontic 
bracket) after peeling or removing the matrix from the 
surface. From FIG. 3 it can be seen that the greatest loss of 
Weight occurred When poly(ethylene glycol) 4000 (PEG4) 
Was employed as the hydrophilic polymer in the formula 
tion. Thermal analysis using DSC shoWed only slight dif 
ferences in the initial and ?nal melting points of the 
matrices, regardless of Which hydrophilic polymer Was used, 
as Well as the melting point of benZocaine (FIG. 4). It should 
be noted that the melting point of benZocaine (88—90° C.) 
Was slightly depressed in all the formulations, although the 
hydrophilic polymer in the formulation had little effect on 
this value. The formulation containing PEO exhibited an 
additional broad peak on the thermogram indicative of a 
physical interaction betWeen PEO and benZocaine. 
A subsequent series of experiments Was performed to 
determine the tragacanth-containing formulation With the 
optimal properties for this application. The percentages of 
the four components Were varied (tragacanth:Wax ratio of 
0—0.2; 0—5% Span 80; 10—40% benZocaine), and the result 
ing release rates Were measured. When the benZocaine 
concentration in the formulation Was increased, a marked 
increase in release rates Was observed. Increasing the con 
centration of Span 80 in the formulation had little effect on 
benZocaine release as long as the benZocaine concentration 
Was 20% or less. When the ratio of tragacanth to Wax Was 
increased from 0.1 to 0.2, an increase in benZocaine release 
Was observed; hoWever, the formulation Was observed to 
erode more rapidly. At tragacanth:Wax ratios in excess of 
0.2, the erosion Was unacceptably high. 
Although the present invention has been fully described 
herein, it is to be noted that various changes and modi?ca 
tions are apparent to those skilled in the art. Such changes 
and modi?cations are to be understood as included Within 
the scope of the present invention as de?ned by the 
appended claims. 
What is claimed is: 
1. A formulation useful to relieve discomfort associated 
With irritation due to orthodontic appliances comprising: 
65 to 75% microcrystalline Wax; 
5 to 15% non-ionic polymer; 
15 to 25% topical anesthetic; and 
1 to 5% surfactant. 
2. Aformulation of claim 1, Wherein the ratio of non-ionic 
polymer to microcrystalline Wax is no greater than 0.2. 
3. A formulation of claim 2, Wherein said topical anes 
thetic is a solid having a particle siZe smaller than a 100 
mesh screen. 
4. Aformulation of claim 2, Wherein the topical anesthetic 
is benZocaine. 
5. A formulation of claim 4, Wherein the non-ionic poly 
mer is tragacanth. 
6. A formulation of claim 5, Wherein the surfactant is 
Span80. 
7. A formulation of claim 6, Wherein, of the total, the 
tragacanth is 7.1%, the microcrystalline Wax is 70.9%, the 
Span80 is 2.0% and the benZocaine is 20.0%. 
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8. Amethod of reducing pain due to mucosal abrasions in 
a patient in need of such pain reduction, comprising admin 
istering a formulation of claim 7. 
9. A formulation of claim 1, Wherein the topical anesthetic 
is selected from the group consisting of: benZocaine; 
lidocaine; novocaine; procaine; butalaine; and dyclonine. 
10. A formulation of claim 1, Wherein the non-ionic 
polymer is selected from the group consisting of: sodium 
carboxymethyl cellulose; Carbopol ETD 2001 resin; traga 
canth; poly (ethylene oxide); methylcellulose; hydroxypro 
pylmethylcellulose; karya gum; cellulose; soluble starch; 
gelatin; poly (vinyl pyrrolidone); poly (ethylene glycol) 
8000; poly (ethylene glycol) 4000; and poly (vinyl alcohol). 
11. A formulation of claim 1, Wherein the surfactant is 
selected from the group consisting of: sorbitan monolaurate, 
polysorbate 80, Spans and TWeens. 
12. A method of reducing pain due to mucosal abrasions 
in a patient in need of such pain reduction, comprising 
administering a formulation of claim 1. 
13. A method to prepare a formulation of claim 1, com 
prising: 
melting the microcrystalline Wax using at least one tem 
perature in the range of approximately 65 to 70° C.; and 
adding the non-ionic polymer and the surfactant to said 
melted microcrystalline Wax, With stirring; and 
adding the topical anesthetic With particle siZe less than 
the apertures in a 100 mesh screen, With mixing, so as 
to obtain a homogenous mixture of said anesthetic, 
Wax, polymer and surfactant; and 
cooling said mixture at a constant rate, With continuous 
agitation, so as to congeal the mixture into a homoge 
neous matrix. 
14. A method of claim 13, Wherein the topical anesthetic 
is selected from the group consisting of: benZocaine; 
lidocaine; novocaine; procaine; butalaine; and dyclonine. 
15. A method of claim 14, Wherein the non-ionic polymer 
is selected from the group consisting of: sodium carboxym 
ethyl cellulose; Carbopol ETD 2001 resin; tragacanth; poly 
(ethylene oxide); methylcellulose; hydroxypropylmethylcel 
lulose; karya gum; cellulose; soluble starch; gelatin; poly 
(vinyl pyrrolidone); poly (ethylene glycol) 8000; poly 
(ethylene glycol) 4000; and poly (vinyl alcohol). 
16. A method of claim 15, Wherein the surfactant is 
selected from the group consisting of: sorbitan monolaurate 
and polysorbate 80. 
17. A method of claim 13, Wherein the homogeneous 
matrix is formed into uniform pieces of a siZe appropriate to 
place on individual dental brackets. 
18. A method of claim 13, Wherein the topical anesthetic 
is benZocaine. 
19. A method of claim 18, Wherein the non-ionic polymer 
is tragacanth. 
20. A method of claim 19, Wherein the surfactant is 
Span80. 
21. A method of claim 20, Wherein, of the total, the 
tragacanth is 7.1%, the microcrystalline Wax is 70.9%, the 
Span80 is 2.0% and the benZocaine is 20.0%. 
* * * * * 
